Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zai Lab's KarXT NDA Accepted for Schizophrenia Treatment
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia.
Product Name : KarXT
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 17, 2025
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zai Lab Reports Positive Phase 3 Results for KarXT in Treating Schizophrenia
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia.
Product Name : KarXT
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 29, 2024
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paliperidone Palmitate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NDA For Luye Pharma’s Paliperidone Palmitate Submitted in The U.S.
Details : Erzofri (paliperidone palmitate) is an 5-HT2a and D2 receptor antagonist which is indicated for the treatment of schizophrenia and schizoaffective disorder.
Product Name : LY03010
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 10, 2023
Lead Product(s) : Paliperidone Palmitate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paliperidone Palmitate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LY03010 (paliperidone palmitate) Prolonged Release Suspension for Injection is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Product Name : LY03010
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2023
Lead Product(s) : Paliperidone Palmitate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paliperidone Palmitate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LY03010 (paliperidone palmitate) injection is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Product Name : LY03010
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 28, 2022
Lead Product(s) : Paliperidone Palmitate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paliperidone Palmitate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Luye Pharma’S Innovative Formulation LY03010 Meets Endpoints in Pivotal U.S. Study
Details : LY03010 (paliperidone palmitate) extended-release injectable suspension is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Product Name : LY03010
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2022
Lead Product(s) : Paliperidone Palmitate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paliperidone Palmitate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Luye Pharma’S Innovative Formulation LY03010 Begins Pivotal Study in the U.S.
Details : LY03010 (paliperidone palmitate) extended-release injectable suspension is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Product Name : LY03010
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 22, 2020
Lead Product(s) : Paliperidone Palmitate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ansofaxine HCl
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Indicated for depression, LY03005 is a serotonin-norepinephrine-dopamine triple reuptake inhibitor developed by Luye Pharma’s New Chemical and Therapeutic Entities R&D platform.
Product Name : LY03005
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 14, 2020
Lead Product(s) : Ansofaxine HCl
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable